A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Dold C. et al, (2025), Science Translational Medicine, 17
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Ibarz-Pavon AB. et al, (2025), Vaccine, 56
A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia.
Viz-Lasheras S. et al, (2025), iScience, 28
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
Evaluation of naturally occurring IgG anti-Vi antibody titers as predictors and correlates of typhoid fever in Dhaka, Bangladesh.
Khanam F. et al, (2025), BMC Infect Dis, 25
A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment.
Viz-Lasheras S. et al, (2025), Nat Commun, 16
Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference
Amodio D. et al, (2025), Vaccine, 43
The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children.
Kristensen M. et al, (2024), Cell Rep Med, 5
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Conlin K. et al, (2024), Vaccine, 45
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
Terstappen J. et al, (2024), Lancet Infect Dis, 24, e747 - e761
GeM-LR: Discovering predictive biomarkers for small datasets in vaccine studies.
Lin L. et al, (2024), PLoS Comput Biol, 20
Respiratory Syncytial Virus-related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study.
Wiseman DJ. et al, (2024), Am J Respir Crit Care Med, 210, 994 - 1001
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
New programme to prevent bronchiolitis in infants
Pollard AJ. et al, (2024), Archives of Disease in Childhood
Characterising the molecular epidemiology of human parechovirus in young infants in the UK and Canada.
Kadambari S. et al, (2024), J Clin Virol, 174
Inflammation of the nasal mucosa is associated with susceptibility to experimental pneumococcal challenge in older adults.
Urban BC. et al, (2024), Mucosal Immunol, 17, 973 - 989